Login to Your Account

GW Sets Terms for U.S. IPO; $40M for Cannabinoid Drugs

By Jennifer Boggs
Managing Editor

Monday, April 22, 2013
UK-based GW Pharmaceuticals plc set the terms for its proposed U.S. initial public offering (IPO), which would provide a listing on Nasdaq and nearly double its cash position ahead of the anticipated launch of lead cannabinoid product Sativex in the U.S.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription